Nothing in US patent law has a more drastic effect on an inventor's patent than a finding of inequitable conduct, so understanding the principles of the doctrine can be valuable in saving your patent from being found unenforceable.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
37 CFR §1.56 (1977).
42 Fed. Reg. 5589 (Jan. 28, 1977).
725 F.2d 1350, 1362–1363 (Fed. Cir. 1984).
57 Fed. Reg. 2021 (1992).
437 F.3d 1309 (Fed. Cir. 2006).
120 F.3d 1253 (Fed. Cir. 1997).
329 F.3d 1358 (Fed. Cir. 2003).
323 F.3d 1354 (Fed. Cir. 2003).
319 F.Supp. 2d 1011 (N.D. Cal. 2004).
437 F.3d 1181 (Fed. Cir. 2006).
Author information
Author notes
Anthony Michael: patent attorney based in New York.
- Anthony Michael
Rights and permissions
About this article
Cite this article
Michael, A. Biotech patents and the inequitable conduct doctrine. Nat Biotechnol 24, 1219–1221 (2006). https://doi.org/10.1038/nbt1006-1219
Issue Date:
DOI: https://doi.org/10.1038/nbt1006-1219